tiprankstipranks
Trending News
More News >
Rigel (RIGL)
NASDAQ:RIGL
Advertisement

Rigel (RIGL) AI Stock Analysis

Compare
1,518 Followers

Top Page

RIGL

Rigel

(NASDAQ:RIGL)

Select Model
Select Model
Select Model
Outperform 71 (OpenAI - 4o)
Rating:71Outperform
Price Target:
$33.00
▲(11.86% Upside)
Rigel's strong financial performance and positive earnings call are major strengths, driving the overall score. However, technical analysis indicates bearish momentum, and high leverage remains a concern. The stock's undervaluation presents an opportunity, but investors should be cautious of potential risks.
Positive Factors
Revenue Growth
Strong revenue growth indicates robust demand for Rigel's products, enhancing its market position and financial health.
Global Market Expansion
Expanding global market access strengthens Rigel's competitive position and diversifies revenue streams, supporting long-term growth.
Cash Generation
Strong cash generation enhances Rigel's ability to invest in R&D and manage debt, supporting sustainable growth.
Negative Factors
High Leverage
High leverage can strain Rigel's financial flexibility and increase risk, potentially impacting long-term stability.
Negative Return on Equity
Negative ROE indicates potential inefficiencies in capital use, which could hinder long-term profitability and shareholder value.
Operational Challenges
Volatility in operational margins can signal underlying business challenges, affecting Rigel's ability to maintain profitability.

Rigel (RIGL) vs. SPDR S&P 500 ETF (SPY)

Rigel Business Overview & Revenue Model

Company DescriptionRigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
How the Company Makes MoneyRigel Pharmaceuticals generates revenue through several key streams, primarily from the commercialization of its approved therapies. The company earns money by selling its marketed drugs, which include treatments for specific hematologic conditions. Additionally, Rigel may receive milestone payments and royalties from partnerships with larger pharmaceutical companies that involve co-development or licensing agreements for its drug candidates. Research and development collaborations also contribute to its revenue, allowing Rigel to leverage its technology and expertise while sharing costs and risks with partners. The success of its clinical trials and the subsequent approval of new therapies are critical factors influencing its earnings potential.

Rigel Earnings Call Summary

Earnings Call Date:Aug 05, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Nov 06, 2025
Earnings Call Sentiment Positive
The earnings call was overwhelmingly positive, highlighting significant sales growth across all products, increased revenue guidance, strong financial performance, and successful market expansion strategies. While there was a minor reevaluation in patient responder data, it did not significantly detract from the overall positive performance and outlook for the company.
Q2-2025 Updates
Positive Updates
Record Net Product Sales
Achieved net product sales of more than $58 million in Q2 2025, marking a 76% year-over-year increase and the company's best quarter ever.
Significant Revenue Growth and Updated Guidance
Total revenue for Q2 2025 was $101.7 million. The company raised its total revenue guidance for 2025 to $270-$280 million, up from $200-$210 million, reflecting anticipated growth of 45% to 52% compared to 2024.
Strong Performance of Commercial Products
TAVALISSE reported $40.1 million in net product sales, a 52% increase year-over-year. GAVRETO generated $11.8 million, and REZLIDHIA $7 million, marking a significant increase for all products.
Successful Financial Management
Rigel generated $59.6 million in net income and increased its cash balance to over $108 million in Q2 2025.
Expansion of Global Market Access
TAVALISSE is now commercially available in Japan, Europe, Canada, Israel, and South Korea, expanding its global footprint.
Negative Updates
Patient Responder Reevaluation
A patient in the R289 study previously reported as a responder was reclassified due to unreported transfusions, affecting study results.
Company Guidance
During the second quarter of 2025, Rigel Pharmaceuticals demonstrated substantial progress, achieving net product sales of over $58 million, marking a 76% increase year-over-year, and total revenues of $101.7 million, including $42.7 million from contract collaborations. The company recognized $40 million in noncash revenue from their collaboration with Lilly, contributing to a net income of $59.6 million and an increased cash balance of $108.4 million. Rigel's updated financial guidance for 2025 projects total revenues between $270 million and $280 million, with net product sales of $210 million to $220 million, reflecting anticipated growth of 45% to 52% compared to 2024. The growth trajectory was attributed to demand across Rigel's commercial products, TAVALISSE, GAVRETO, and REZLIDHIA, and improved patient affordability due to policy changes. The company also emphasized continued financial discipline and strategic development of their hematology and oncology pipeline, including the Phase 1b study of R289 and the exploration of olutasidenib's potential in IDH1 mutated cancers.

Rigel Financial Statement Overview

Summary
Rigel shows strong revenue growth and profitability improvements, with a high gross profit margin and significant cash flow generation. However, the high debt-to-equity ratio and negative return on equity are concerns.
Income Statement
78
Positive
Rigel's income statement shows strong revenue growth with a 31.93% increase in TTM, indicating robust sales performance. The gross profit margin remains high at 89.64%, reflecting efficient cost management. The net profit margin improved significantly to 18.31%, showcasing enhanced profitability. However, historical volatility in EBIT and EBITDA margins suggests potential operational challenges.
Balance Sheet
55
Neutral
The balance sheet reveals a high debt-to-equity ratio of 3.29 in TTM, indicating significant leverage, which could pose financial risk. Despite this, the company has improved its equity position over time. The return on equity is negative, suggesting inefficiencies in generating returns from shareholders' equity.
Cash Flow
82
Very Positive
Rigel's cash flow statement is strong, with an impressive 85.33% growth in free cash flow in TTM, indicating improved cash generation. The free cash flow to net income ratio is healthy at 1.00, showing effective conversion of profits into cash. However, the operating cash flow to net income ratio is moderate, suggesting room for improvement in operational cash efficiency.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue267.92M179.28M116.88M120.24M149.24M108.62M
Gross Profit245.19M160.63M109.77M118.49M148.15M107.73M
EBITDA109.30M28.51M-16.98M-53.87M-11.29M-27.68M
Net Income97.82M17.48M-25.09M-58.57M-17.91M-29.74M
Balance Sheet
Total Assets206.74M163.98M117.22M134.28M167.33M110.38M
Cash, Cash Equivalents and Short-Term Investments108.38M77.32M56.93M58.21M124.97M57.33M
Total Debt61.04M59.97M60.58M41.55M30.57M39.09M
Total Liabilities124.80M160.69M145.87M147.90M136.95M76.35M
Stockholders Equity81.93M3.29M-28.64M-13.62M30.37M34.03M
Cash Flow
Free Cash Flow66.15M31.43M-20.74M-74.21M5.25M-53.45M
Operating Cash Flow65.83M31.47M-5.74M-73.76M5.88M-52.19M
Investing Cash Flow-40.94M4.13M-4.30M72.78M-80.04M47.47M
Financing Cash Flow-7.47M-11.64M18.37M6.55M62.67M12.57M

Rigel Technical Analysis

Technical Analysis Sentiment
Positive
Last Price29.50
Price Trends
50DMA
33.80
Negative
100DMA
26.75
Positive
200DMA
23.01
Positive
Market Momentum
MACD
-1.88
Positive
RSI
37.69
Neutral
STOCH
32.70
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RIGL, the sentiment is Positive. The current price of 29.5 is below the 20-day moving average (MA) of 32.25, below the 50-day MA of 33.80, and above the 200-day MA of 23.01, indicating a neutral trend. The MACD of -1.88 indicates Positive momentum. The RSI at 37.69 is Neutral, neither overbought nor oversold. The STOCH value of 32.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RIGL.

Rigel Risk Analysis

Rigel disclosed 59 risk factors in its most recent earnings report. Rigel reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Rigel Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
71
Outperform
$518.39M5.45376.09%105.62%
61
Neutral
$512.39M-65.30%1504.83%56.81%
55
Neutral
$540.00M-62.49%74.95%34.25%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
45
Neutral
$570.39M-31.58%-51.13%7.57%
44
Neutral
$529.90M-437.92%-78.63%1.88%
39
Underperform
$488.59M-80.09%60.14%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
RIGL
Rigel
29.50
13.80
87.90%
LXRX
Lexicon Pharmaceuticals
1.52
-0.16
-9.52%
VSTM
Verastem
9.00
6.08
208.22%
RGNX
RegenXBio
10.51
0.95
9.94%
BCYC
Bicycle Therapeutics
8.00
-15.53
-66.00%
OPT
Opthea Limited Sponsored ADR
3.20
-1.42
-30.74%

Rigel Corporate Events

Executive/Board ChangesShareholder Meetings
Rigel Pharmaceuticals Approves Equity Plan Amendment
Neutral
May 23, 2025

On May 22, 2025, Rigel Pharmaceuticals, Inc. held its 2025 Annual Meeting of Stockholders, where stockholders approved an amendment to the 2018 Equity Incentive Plan, adding 700,000 shares for issuance. The plan became effective immediately upon approval. Additionally, stockholders elected directors to serve until the 2028 Annual Meeting, approved executive compensation, and ratified Ernst & Young LLP as the independent accounting firm for the fiscal year ending December 31, 2023.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 08, 2025